echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Shutaishen STSA-1002 injection was approved for clinical use in the United States

    Shutaishen STSA-1002 injection was approved for clinical use in the United States

    • Last Update: 2021-08-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On July 19, Shutaishen issued an announcement stating that it had received a notification email from the US FDA, and started clinical trials with STSA-1002 injection for the treatment of severe COVID-19 indications


    STSA-1002 injection is a recombinant anti-human C5a IgG1 fully human monoclonal antibody targeting C5a.


    In recent years, with the continuous deepening of basic research, the role of the complement system in a variety of major diseases has received more and more attention and affirmation


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.